tbuckley/cabot-search huggingface dataset:
Correlation of markers of oxidative damage and circulating IL6 levels with survival following treatment with bevacizumab in metastatic colorectal cancer patients.
Authors: Sinead Noonan, Petra Martin, Aoife Maguire, Monika Biniecka, Miriam Tosetto, John Hyland, Kieran Sheahan, Diarmuid O'Donoghue, Hugh Mulcahy, David Fennelly, Jacintha O'Sullivan
Journal: Journal of Clinical Oncology (2012)

e21024 Background: Angiogenesis drives cancer growth, tumour progression and metastases. Hypoxic tumours initiate recruitment of their own blood supply and enhance expression of vascular endothelial growth factor (VEGF). Bevacizumab is a recombinant humanised monoclonal anti-VEGF antibody which prevents VEGF binding to its receptors and improves overall survival in metastatic colorectal cancer patients when combined with cytotoxic chemotherapy. Currently, Bevacizumab is indicated as a first line treatment in all metastatic colorectal cancer patients, however only 38-44% of these patients will have a response to treatment. There is no good marker to predict treatment response. The role of inflammation and oxidative damage in driving angiogenesis and clinical response to bevacizumab is poorly understood. The aim of this study was to investigate the levels of oxidative damage and inflammation in the tissue and in the circulation of patients receiving Bevacizumab. Methods: Tissue from 80 patients was constructed into tissue microarrays (TMAs) and screened by immunohistochemistry for the levels of a DNA adduct marker 8oxodG and a lipid peroxidation marker 4HNE in addition to Ki67 status. Serum was screened for 8oxodG, 4HNE and the inflammatory cytokines; IL1β, IL6, IL8, TNFα and pro-angiogenic factors; Ang 2, TGFβ, VEGF using ELISA. Data was correlated with patient survival following Bevacizumab treatment. Results: 8oxodG stromal nuclear positivity significantly correlated with survival following bevacizumab (p=0.035) and this was independent of cell proliferation status. Following multivariate analysis, circulating IL6 levels also significantly correlated with survival following bevacizumab treatment (p=0.01). Using linear regression, circulating levels of 8oxodG correlated with IL6 levels (p=0.016). Circulating Ang 2 levels correlated with IL6 (p=0.006). Conclusions: We have shown for the first time that levels of a DNA adduct marker 8oxodG and circulating levels of IL6 correlate with survival in metastatic patients receiving Bevacizumab.
OUTCOMES OF TRANSCATHETER AORTIC VALVE REPLACEMENT WITHOUT BALLOON PREDILATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Krishna Kandregula, Kinjal Banerjee, Brandon Jones, Yash Jobanputra, Amar Krishnaswamy, Stephanie Mick, Jose Navia, Zoran Popovic, Lars Svensson, E. Murat Tuzcu, Samir Kapadia
Journal: Journal of the American College of Cardiology (2017)
Lysosomal rupture induced by structurally distinct chitosans either promotes a type 1 IFN response or activates the inflammasome in macrophages
Authors: David Fong, Pascal Grégoire-Gélinas, Alexandre P. Cheng, Tal Mezheritsky, Marc Lavertu, Sachiko Sato, Caroline D. Hoemann
Journal: Biomaterials (2017)

Chitosan is a family of glucosamine and N-acetyl glucosamine polysaccharides with poorly understood immune modulating properties. Here, functional U937 macrophage responses were analyzed in response to a novel library of twenty chitosans with controlled degree of deacetylation (DDA, 60-98%), molecular weight (1 to >100 kDa), and acetylation pattern (block vs. random). Specific chitosan preparations (10 or 190 kDa 80% block DDA and 3, 5, or 10 kDa 98% DDA) either induced macrophages to release CXCL10 and IL-1ra at 5-50 μg/mL, or activated the inflammasome to release IL-1β and PGE2 at 50-150 μg/mL. Chitosan induction of these factors required lysosomal acidification. CXCL10 production was preceded by lysosomal rupture as shown by time-dependent co-localization of galectin-3 and chitosan and slowed autophagy flux, and specifically depended on IFN-β paracrine activity and STAT-2 activation that could be suppressed by PGE2. Chitosan induced a type I IFN paracrine response or inflammasome response depending on the extent of lysosomal rupture and cytosolic foreign body invasion. This study identifies the structural motifs that lead to chitosan-driven cytokine responses in macrophages and indicates that lysosomal rupture is a key mechanism that determines the endogenous release of either IL-1ra or IL-1β.
The impact of HBO on early ALC recovery following high-dose therapy and autologous transplantation.
Authors: Omar Salah Aljitawi, Mary Markiewicz, Amara Seng, Tara L. Lin, Siddhartha Ganguly, Jonathan Mahnken, Anurag Singh, Leyla Shune, Sunil H. Abhyankar, Brea Lipe, Dennis Allin, Joseph McGuirk, Thomas Yankee
Journal: Journal of Clinical Oncology (2015)

7034 Background: Historically, early absolute lymphocyte count (ALC) recovery (defined as ALC of 500 cells/microL day 15 of transplant) is seen in around 50% of patients receiving autologous stem cell transplantation (ASCT) and is associated with improved survival. Early ALC recovery is related to recovery of natural killer (NK) cells mediated by interluken-15 (IL-15). We are currently conducting a pilot study primarily investigating hyperbaric oxygen (HBO) as a modality to facilitate blood count recovery in ASCT setting. By lowering erythropoietin (EPO) at time of hematopoietic stem cell (HSC)/progenitor cell infusion, HBO appears to facilitate bone marrow homing of HSC/progenitors with retained multi-lineage potential. Accordingly, we hypothesized that HBO pre-treatment might facilitate early ALC recovery. Methods: Patients treated on the ongoing pilot study were evaluated for ALC recovery, as previously defined. Blood samples were collected at baseline (prior to high-dose chemotherapy), day 0 (prior to HBO and 6 hours later), 24- and 48-hours following HBO therapy, and on the third day of neutrophil engraftment. Plasma IL-15 was measured by ELISA. Results: Of the twenty patients who were treated on study, one patient did not tolerate HBO therapy and 2 patients were released to their oncologist prior to day 15 post-ASCT, accordingly 17 patients were assessable for ALC recovery. 13 out of the 17 patients (76%) achieved ALC 500 prior to day 15, and all achieved ALC 500 by day 18 post-ASCT. In our cohort, the median time to achievement of ALC 500 was 12 (8-18) days. To date, twelve patients had IL-15 levels measured in pg/ml for all time points except baseline level which was measured in 5 patients. Average IL-15 level was higher on day 0 prior to HBO therapy compared to baseline level (22.83 +/- 3.20 vs 4.94+/-1.38) and third day of neutrophil engraftment IL-15 level was higher than baseline level (13.1 +/- 1.7 vs 4.94 +/-1.38). IL-15 level peaked 48-hours following HBO therapy (31.9 +/-3.67). Conclusions: Compared to historic data, the rate of early ALC recovery in our HBO pilot study appears to be encouraging. HBO effects on post-ASCT ALC recovery and IL-15 warrant further evaluation. Clinical trial information: NCT02087657.
ORTHOPNEA OR PAROXYSMAL NOCTURNAL DYSPNEA IN OLDER ADULTS WITHOUT PREVALENT HEART FAILURE IS A PREDICTOR, BUT NOT AN INDEPENDENT RISK FACTOR FOR INCIDENT HEART FAILURE: INSIGHTS FROM THE CARDIOVASCULAR HEALTH STUDY
Authors: Apostolos Tsimploulis, Poonam Bhyan, Phillip Lam, Daniel Dooley, Javed Butler, Prakash Deedwania, Gregg Fonarow, Wen-Chi Wu, Marc Blackman, Charity Morgan, Qing Treitler Zeng, Michel White, Ioannis Kanonidis, Wilbert Aronow, Deepak Bhatt, Stefan Anker, Ali Ahmed
Journal: Journal of the American College of Cardiology (2017)
A comparison of cutaneous melanoma patients who recur following a negative sentinel lymph node biopsy to those with a positive sentinel lymph node biopsy.
Authors: Edward L Jones, Alessandro Paniccia, Teresa S Jones, Justin Merkow, Maggie Hodges, Joshua T Byers, Robert Stovall, Nicole Kounalakis, Nathan W. Pearlman, Csaba Gajdos, Rene Gonzalez, Karl D. Lewis, William Robinson, Martin McCarter
Journal: Journal of Clinical Oncology (2014)

9065 Background: Sentinel lymph node biopsy (SLNB) for cutaneous melanoma yields powerful prognostic information. Patients with a negative SLNB who recur experience worse outcomes than those with a positive SLNB based upon subgroup analysis in the Multicenter Selective Lymphadenectomy Trial (MSLT-1). The PURPOSE of this study was to compare our patients who recur following a negative SLNB to those with a positive SLNB. Methods: Retrospective chart review of a prospectively created database of patients with cutaneous melanoma undergoing SLNB from February 1995 to January 2013. Results: Of 1017 patients who underwent SLNB, 170 (17%) recurred after a negative biopsy: 60 (35%) were local/in-transit recurrences, 33 (19%) regional and 73 (43%) distant at a median 27 months (range 15-50 months). One hundred and fifty-seven (15%) patients had a positive SLNB of which 131 (77%) underwent completion lymph node dissection (CLND). Fifty-six (36%) of those patients recurred a median 14 months later (range 8-30 months). The median length of follow-up for entire cohort was 43 months (range 1-170 months). Patients with recurrence after a negative SLNB were more likely to be male (64% vs. 50%, p=0.02) but age, Breslow depth, ulceration, mitotic activity and the use of adjuvant therapy were not statistically different. Twenty-nine (88%) of the 33 patients with regional recurrence after a negative SLNB underwent CLND. These patients had significantly more positive nodes in the CLND specimens than those undergoing CLND for a positive SLNB (69% vs. 22%, p<0.001). While disease-specific survival was not significantly different between patients with recurrence after a negative SLNB versus a positive SLNB at 5 years (56% vs.77%, p=0.14) this became significant at 10 years (28% vs. 68%, p<0.001). Conclusions: Patients with cutaneous melanoma who recur following a negative sentinel lymph node biopsy have worse survival when compared to those with a positive biopsy. These findings support the subgroup analysis of the MSLT-1 trial and suggest that patients with recurrence following a negative sentinel lymph node biopsy exhibit aggressive tumor biology.
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial
Authors: Raffaele De Caterina, Giulia Renda, Anthony P. Carnicelli, Francesco Nordio, Marco Trevisan, Michele F. Mercuri, Christian T. Ruff, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano
Journal: Journal of the American College of Cardiology (2017)

The use of non-vitamin K antagonist oral anticoagulants (NOACs) instead of vitamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and coexisting valvular heart disease (VHD) is of substantial interest. This study explored outcomes in patients with AF with and without VHD in the ENGAGE AF–TIMI 48 (Effective Anticoagulation with factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial, comparing edoxaban with warfarin. Valvular heart disease was defined as history or baseline echocardiography evidence of at least moderate aortic/mitral regurgitation, aortic stenosis, or prior valve surgery (bioprosthesis replacement, valve repair, valvuloplasty). Patients with moderate to severe mitral stenosis or mechanical heart valves were excluded from the trial. Comparisons were made of rates of stroke/systemic embolic event (SSEE), major bleeding, additional efficacy and safety outcomes, as well as net clinical outcomes, in patients with or without VHD treated with edoxaban or warfarin, using adjusted Cox proportional hazards. After adjustment for multiple baseline characteristics, compared with no-VHD patients (n = 18,222), VHD patients (n = 2,824) had a similar rate of SSEE but higher rates of death (hazard ratio [HR]: 1.40; 95% confidence interval [CI]:1.26 to 1.56; p <0.001), major adverse cardiovascular events (HR: 1.29; 95% CI: 1.16 to 1.43; p <0.001), and major bleeding (HR: 1.21; 95% CI: 1.03 to 1.42; p = 0.02). Higher-dose edoxaban regimen had efficacy similar to warfarin in the presence of VHD (for SSEE, HR: 0.69; 95% CI: 0.44 to 1.07, in patients with VHD, and HR: 0.91; 95% CI: 0.77 to 1.07, in patients without VHD; p interaction [pint] = 0.26; and for less major bleeding, HR: 0.74; 95% CI: 0.53 to 1.02 in patients with VHD, and HR: 0.82; 95% CI: 0.71 to 0.94, in patients with no VHD; pint = 0.57). The presence of VHD increased the risk of death, major adverse cardiovascular events, and major bleeding but did not affect the relative efficacy or safety of higher-dose edoxaban versus warfarin in AF. (Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs. Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation [ENGAGE AF-TIMI 48]; NCT00781391)
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
Authors: Hugh Calkins, Stephan Willems, Edward P. Gerstenfeld, Atul Verma, Richard Schilling, Stefan H. Hohnloser, Ken Okumura, Harvey Serota, Matias Nordaby, Kelly Guiver, Branislav Biss, Marc A. Brouwer, Massimo Grimaldi
Journal: New England Journal of Medicine (2017)

Catheter ablation of atrial fibrillation is typically performed with uninterrupted anticoagulation with warfarin or interrupted non-vitamin K antagonist oral anticoagulant therapy. Uninterrupted anticoagulation with a non-vitamin K antagonist oral anticoagulant, such as dabigatran, may be safer; however, controlled data are lacking. We investigated the safety of uninterrupted dabigatran versus warfarin in patients undergoing ablation of atrial fibrillation.In this randomized, open-label, multicenter, controlled trial with blinded adjudicated end-point assessments, we randomly assigned patients scheduled for catheter ablation of paroxysmal or persistent atrial fibrillation to receive either dabigatran (150 mg twice daily) or warfarin (target international normalized ratio, 2.0 to 3.0). Ablation was performed after 4 to 8 weeks of uninterrupted anticoagulation, which was continued during and for 8 weeks after ablation. The primary end point was the incidence of major bleeding events during and up to 8 weeks after ablation; secondary end points included thromboembolic and other bleeding events.The trial enrolled 704 patients across 104 sites; 635 patients underwent ablation. Baseline characteristics were balanced between treatment groups. The incidence of major bleeding events during and up to 8 weeks after ablation was lower with dabigatran than with warfarin (5 patients [1.6%] vs. 22 patients [6.9%]; absolute risk difference, -5.3 percentage points; 95% confidence interval, -8.4 to -2.2; P<0.001). Dabigatran was associated with fewer periprocedural pericardial tamponades and groin hematomas than warfarin. The two treatment groups had a similar incidence of minor bleeding events. One thromboembolic event occurred in the warfarin group.In patients undergoing ablation for atrial fibrillation, anticoagulation with uninterrupted dabigatran was associated with fewer bleeding complications than uninterrupted warfarin. (Funded by Boehringer Ingelheim; RE-CIRCUIT ClinicalTrials.gov number, NCT02348723 .).
DIAGNOSTIC ACCURACY OF CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY IN AORTIC STENOSIS PATIENTS REFERRED FOR AORTIC VALVE REPLACEMENT: SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Kongkiat Chaikriangkrai, Ghanshyam Palamaner Subash Shantha, Aref Bin Abdulhak, Rudhir Tandon, Musab Alqasrawi, Hye Yeon Jhun, Gardar Sigurdsson
Journal: Journal of the American College of Cardiology (2017)
TREND OF USE IN TRANSRADIAL INTERVENTION AMONG ELDERLY PATIENTS IN JAPAN ACCORDING TO THEIR PRE-PROCEDURAL BLEEDING RISK
Authors: Yohei Akiba, Ayaka Endo, Nobuhiro Ikemura, Mitsuaki Sawano, Susumu Nakagawa, Toshiyuki Takahashi, Yohei Numasawa, Masahiro Suzuki, Shigetaka Noma, Shun Kohsaka, Keiichi Fukuda
Journal: Journal of the American College of Cardiology (2017)
Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients
Authors: Chris L. Pashos, Brian GM Durie, Robert Rifkin, Howard Terebelo, Cristina Gasparetto, Jayesh Mehta, Kathleen Toomey, Rafat Abonour, Rafael Fonseca, Mohit Narang, Jatin J Shah, Arlene S Swern, Kristen A Sullivan, Thomas K. Street, Zeba M. Khan
Journal: Blood (2011)
Clinical Features and Prognostic Factors in 135 NHL of the Head and Neck Treated by the GOELAMS 02 Trial.
Authors: Laurent Laccourreye, Bernard Desablens, Christine Le Maignan, Anne Le Mevel, Christian Berthou, Thierry Lamy, Christiane Ghandour, François Guilhot, Mathilde Hunault-Berger, Henry Jardel, Norbert Ifrah, Philippe Colombat
Journal: Blood (2005)
A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse.
Authors: Karim Fizazi, Muriel Habibian, Agnes Laplanche, Herve Baumert, Riccardo Valdagni, Joan Carles, Pierre Blanchard
Journal: Journal of Clinical Oncology (2014)

TPS5098 Background: Most patients (pts) with PC are currently diagnosed with localized disease and most of PC-related deaths occur in high risk (HR) pts due to metastatic dissemination. Combining androgen deprivation therapy (ADT) with radiotherapy (RT) improves the survival of pts with HR localized PC, but the risk of relapse in the HR population warrants investigation. In other epithelial neoplasms, chemotherapy (CT) regimens with proved activity in the metastatic setting often yielded a survival benefit when used in the localized setting. Cabazitaxel (Cbz) has demonstrated survival benefit in metastatic castrate-resistant PC post-docetaxel. One of the objectives is to evaluate the benefit of neoadjuvant Cbz in pts with HR localized PC. Dose-escalated RT benefits have been demonstrated in intermediate and HR PC. Randomized trials failed to demonstrate the superiority of pelvic over prostate only RT. In this trial involving HR PC pts the risk of occult pelvic lymph node metastases might be as high as 30%. With neoadjuvant CT, pelvic RT could help eradicate microscopic pelvic disease and improve PFS. As elective pelvic RT is still controversial, practices might vary between centers and potentially pts receiving Cbz or not. Therefore a second randomization is used to answer this major question concerning RT of the pelvis. Methods: This factorial design international trial started in December 2013 and aims to recruit 1048 pts with at least 2 HR criteria among Gleason score ≥ 8, T3 (MRI accepted)-T4 and PSA ≥ 20 ng/mL; localized disease (including pelvic lymph nodes > 1 cm) and no prior treatment for PC. Pts are randomized between ADT + prostate-only RT +/- Cbz and ADT + pelvic RT +/- Cbz. Primary endpoint is clinical PFS (cPFS). 262 pts are needed in each of the four arms to detect an absolute difference in cPFS at 6 years of 7.5% (5% 2-sided test, power=80%) between ADT and ADT+CT arms and prostate only RT and pelvic RT arms. Planned accrual duration is 4 years. An interim analysis is planned at 50% of the events. Conclusion: The aim is to evaluate the benefits of neoadjuvant Cbz and pelvic IMRT in HR localized PC. This is a unique opportunity to study this paradigm in a largely powered trial. Clinical trial information: NCT01952223.
ADDITIVITY OF NEBIVOLOL/VALSARTAN SINGLE-PILL COMBINATIONS VERSUS OTHER APPROVED SINGLE-PILL COMBINATIONS FOR HYPERTENSION
Authors: Jack Ishak, Michael Rael, Henry Punzi, Alan Gradman, Lynn M. Anderson, Mehul D. Patel, Sanjida Ali, William Ferguson, Joel Neutel
Journal: Journal of the American College of Cardiology (2017)
LONG-TERM MORTALITY IN PERCUTANEOUS CORONARY INTERVENTION OF SAPHENOUS VEIN GRAFTS FROM REAL-WORLD REGISTRY DATA
Authors: Ron Waksman, Kyle Buchanan, M. Chadi Alraies, Toby Rogers, Arie Steinvil, Edward Koifman, Rebecca Torguson, Itsik Ben-Dor, Augusto Pichard, Lowell Satler
Journal: Journal of the American College of Cardiology (2017)
Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice
Authors: Idoia García-Ramírez, Saber Tadros, Inés González-Herrero, Alberto Martín-Lorenzo, Guillermo Rodríguez-Hernández, Dalia Moore, Lucía Ruiz-Roca, Oscar Blanco, Diego Alonso-López, Javier De Las Rivas, Keenan Hartert, Romain Duval, David Klinkebiel, Martin Bast, Julie Vose, Matthew Lunning, Kai Fu, Timothy Greiner, Fernando Rodrigues-Lima, Rafael Jiménez, Francisco Javier García Criado, María Begoña García Cenador, Paul Brindle, Carolina Vicente-Dueñas, Ash Alizadeh, Isidro Sánchez-García, Michael R. Green
Journal: Blood (2017)
Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS])
Authors: François Guilhot, Timothy P Hughes, Jorge Cortes, Yanfeng Wang, Michael Hayes, Anthony Gichangi, Brian J. Druker, Michele Baccarani
Journal: Blood (2008)
Assessment of safety and feasibility of HIV protease inhibitors (PI) as antiangiogenic agents in the treatment of advanced nasopharyngeal carcinoma (NPC)
Authors: C. Simonelli, E. Vaccher, F. Martellotta, R. Tedeschi, E. Salvi, C. Sgadari, P. Monini, B. Ensoli, U. Tirelli
Journal: Journal of Clinical Oncology (2004)

3121 Background: HIV-PI inhibit the conversion of the active form of metalloproteinase-2 (MMP-2), thus preventing activation of proteases necessary for angiogenesis. In NPC, MMPs and VEGF are overexposed and their expression correlates with a poor prognosis. Methods: Since January 2002, we started the compassionate use of Indinavir for extensively pretreated pts. The aims of the study were to evaluate: feasibility and safety, serum and/or plasma level of the "anti-angiogenic surrogate markers" (MMP-2, MMP-3, MMP-9, VEGF and β FGF). Pts refractory to first-line, second-line conventional or to high dose chemotherapy (CT) plus ASCT and radiotherapy (RT) and pts who could not receive any intensive CT or RT were allowed to receive Indinavir, 800 mg tid po. alone or with concomitant Carboplatin (AUC 5) every 21 days. Toxicity according to WHO scale and biochemical tests for the "surrogate markers" were performed every 4, 8 weeks. Results: Six pts were enrolled. Five pts received therapy for a median time of 28 wks. One pt withdrew the informed consent after few days. Two pts received Indinavir alone for 16 and 15 weeks then continued Indinavir and Carboplatin for other 12 and 13 weeks. Three pts received Indinavir plus Carboplatin for the whole period. In 4 pts we observed nausea G1, only 1 pt interrupted Indinavir because of nausea G2. We did not observe any occurrence of kidney stones, hyperglycemia or increased level of bilirubin, elevate levels of transaminases. On the contrary, 2 pts showed lipodistrofy (buffalo bump) after 10 and 20 weeks, but cholesterol level was increased above the normal value only in 1 pt, while tryglicerides were normal in all pts. During the concomitant treatment with Carboplatin we observed only 1 G2 anaemia and 1 G1 leucopenia. The surrogate markers were measured in all pts and the results will be discussed in detail at the meeting. Conclusions: Treatment with Indinavir is feasible in pts with advanced NPC and does not increase toxicity due to concomitant use of Carboplatin. The development of lypodistrophy must be taken in account even if it is not a limiting-treatment toxicity in this setting. No significant financial relationships to disclose.
RED CELL DISTRIBUTION WIDTH PREDICTS ADVERSE OUTCOMES IN ADULTS WITH CONGENITAL HEART DISEASE: RESULTS FROM THE BOSTON ADULT CONGENITAL HEART BIOBANK
Authors: Laith Alshawabkeh, Saurabh Rajpal, Michael Landzberg, Catherine Gray, Fred Wu, Georges Ephrem, Alexander Opotowsky
Journal: Journal of the American College of Cardiology (2017)
Atiprimod Inhibits the JAK-STAT Pathway and Induces Apoptosis in Human Cells Carrying the JAK2V617F or JAK3 Mutation.
Authors: Taghi Manshouri, Mirna Golemovic, Hagop M.M. Kantarjian, Jorge E. Cortes, Ying Zhang, Waldemar Priebe, Zeev Estrov, Srdan Verstovsek
Journal: Blood (2007)